Title: SARS-CoV-2 IgM and IgG serology and clinical outcomes in COVID-19 patients

Authors: Mohan S^{1*}, Pratap Kumar^{1*}, Prasan Kumar Panda¹, Vikram Jain, Rohit Raina¹, Sarama Saha², Vivekandan S², Balram J Omar³

Affiliations: ¹Department of Internal Medicine (ID Division), ²Department of Biochemistry, ³Microbiology, AIIMS Rishikesh

Emails: mohansuresh19@gmail.com, pkmaharaj15@gmail.com, motherprasanna@rediffmail.com, vikramjetawat99@gmail.com, rohitraina103@yahoo.com, saramasaha@yahoo.co.in, svivek aiims@yahoo.com, balram.micro@aiimsrishikesh.edu.in

*Equal contribution

Corresponding author

Prasan Kumar Panda

Asso. Professor, Dept. of Medicine,

Sixth Floor, College Block,

All India Institute of Medical Sciences (AIIMS),

Rishikesh, India, 249203

Mob: +91-9868999488

motherprasanna@rediffmail.com

Abstract

Background: The SARS-CoV-2 virus has become pandemic for the last 2 years. Inflammatory response to the virus leads to organ dysfunction and death. Predicting the severity of inflammatory response helps in managing critical patients using serology tests IgG and IgM. We conducted a longitudinal study to correlate serum SARS-CoV-2 IgM and IgG

serology with clinical outcomes in COVID-19 patients.

Methods: We analyzed patient data from March to December of 2020 for those who were admitted at AIIMS Rishikesh. Clinical and laboratory data of these patients were collected from the e-hospital portal and analysed. Correlation was seen with clinical outcomes and was assessed using MS Excel 2010 and SPSS software.

Results: Out of 494 patients, the mean age of patients was 48.95 ± 16.40 years and there were more male patients in the study (66.0%). The patients were classified into 4 groups; mild-moderate 328 (67.1%), severe 131 (26.8%) and critical 30 (6.1%). The mean duration from symptom onset to serology testing was 19.87 ± 30.53 days. In-hospital mortality was observed in 25.1% patients. The seropositivity rate (i.e., either IgG or IgM >10 AU) was 50%. There was a significant difference between the 2 groups in terms of IgM Levels (AU/mL) (W = 33428.000, p = <0.001) and IgG Levels (AU/mL) (W = 39256.500, p = <0.001), with the median IgM/ IgG Levels (AU/mL) being highest in the RT-PCR-Positive group. There was no significant difference between the groups in terms of IgM Levels and IgG levels with all other clinical outcomes (disease severity, septic shock, Intensive care admission, mechanical ventilation and mortality).

Conclusion: Serology (IgM and IgG) levels are high in RTPCR positive group compared to clinical COVID-19. However, serology cannot be useful for the prediction of disease outcomes except few situations. The study also highlights the importance of doing serology at a particular time as antibody titres vary with the duration of the disease.

Keywords: SARS-CoV-2, serology IgM and IgG, RTPCR, Inflammatory response.

Introduction

COVID-19 has affected almost 581 million people with around 6.4 million deaths as of July 2022 (WHO).(1) Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was identified as the causative agent. SARS-CoV-2 causes a respiratory infection with systemic involvement and an estimated 1% death rate. SARS-CoV-2 can infect individuals from different age groups and causes a wide spectrum of disease manifestations ranging from asymptomatic, mild, moderate to severe symptoms with possible fatal outcomes.(2) Age, sex, pre-existing comorbidities, host genetics as well as host immune response are the key factors determining the outcomes.(3)

The RTPCR assay is the right method to diagnose SARS-CoV-2. Unfortunately, the sensitivity of the RNA test in the real world is not satisfactory and, false-negative and false-positive cases have also been reported owing to several factors.(4) According to recent WHO case definitions, the RTPCR negative patients who meet clinical and epidemiological criteria or patients with severe acute respiratory illness who have typical chest imaging features or unexplained anosmia or ageusia are termed as probable COVID-19 patients.(5,6)

Serological tests are increasingly applied for the diagnosis of SARS-CoV-2 infection. Blood levels of immunoglobulin SARS-CoV-2 IgG & IgM, are also deployed for evaluating immune responses and confirming the diagnosis in symptomatic patients presenting outside of the window of positivity for RTPCR-based SARS-CoV-2 testing.(7) Few studies have assessed the utility of seroconversion profiles to predict infection severity or outcomes following SARS-CoV-2 infection. A strong association was observed between the magnitude of antibody response and patient survival, disease severity and fatal outcomes. Furthermore, several studies have documented discrepancy in findings related to the timing of SARS-CoV-2 antibody seroconversion and the onset of symptoms.(8-10) More information about the dynamics of the early humoral immune response is needed to realize the full potential of serological testing for SARS-CoV-2. The dynamics of antibody responses, in COVID-19 patients with different clinical presentations, is still not well-characterized. Such information can help our understanding of the nature of COVID-19 infection and guide patient management.

Here, we studied the seropositivity and kinetics of SARS-CoV-2 IgM and IgG antibodies in blood samples collected between 2 to 85 days post-symptoms onset from a cohort of 493 COVID-19 patients. The objectivity were correlation of the serology (IgM and IgG) with

RTPCR status, disease severity (mild to critical), ICU admission, septic shock, acute kidney

injury, and in hospital mortality.

Material and methods

Study design and setting:

The study is a observational longitudinal study conducted on COVID-19 patients admitted in

a tertiary care hospital, All India Institute of Medical Sciences (AIIMS), Rishikesh, India

from August, 2020 to Nov, 2020. The study was designed according to the Strengthening the

Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.

Inclusion criteria:

1. COVID-19 patients with detectable SARS-CoV-2 RNA in respiratory samples since

disease onset.

2. Clinical COVID-19 patients i.e. cases with clinical manifestations characteristic of

COVID-19 but with negative SARS-CoV-2 RT-PCR test from admission until

discharges (1,2).

3. Patients of both genders with age ≥ 15 years.

Exclusion criteria:

1. Patients not fulfilling COVID-19 diagnostic criteria as per institutional protocol.

2. Asymptomatic patients, pregnant women, and patients having incomplete data

Case definitions:

COVID-19 Severity classification: Patients were classified as mild, moderate, severe, and

critical according to the WHO guidelines (1).

Serological tests: iFlash-SARS-CoV-2 (Shenzhen Yhlo Biotech Co. Ltd.), a paramagnetic

particle based chemiluminescent immunoassay (CLIA) was used for the determination of

IgM and IgG antibodies against SARS-CoV-2 nucleocapsid protein and spike protein.

According to the manufacturer's inserts (V1.0 English Fd. 2020–02-20), the IgM and IgG

cut-off is 10AU/ml. i.e., an antibody titre above titre over 10AU/mL was regarded as

positive.

Treatment of patients: Patients were treated uniformly as per institutional guideline.

Participants' enrolment: All COVID-19 admitted patients at All India Institute of Medical Sciences, Rishikesh during above time period.

Variables and Outcome and Data collection: Full information regarding demographic characteristics, time course of symptoms, time of presentation and testing, presenting symptoms, final diagnosis, treatments received (i.e. oxygen therapy, corticosteroids, ICU admission, invasive ventilation requirement and dialysis) were collected in master excel. The medical records were further critically reviewed for important missed data.

Study size: All consecutive patients during above time period.

Ethics: The Approval for this study was obtained from institute ethics committee of AIIMS Rishikesh with approval no CTRI/2020/08/027169.

Statistical methods: All the statistical analyses were performed using statistical package for social sciences (SPSS), Windows version 23 software package (SPSS, CHICAGO, IL, USA). Non-normally distributed continuous variables were presented as medians (interquartile ranges [IQR]). Differences between non-normally distributed continuous variables were assessed using the Mann–Whitney U test. Categorical variables were presented as counts (%). Differences between categorical variables were assessed using the χ^2 or Fisher's exact tests. A two-sided value of $p \square < \square 0.05$ was considered statistically significant.

Bias: As all patients sampling for IgG and IgM was conducted only once, and time to sampling may be an important variable which can confound the study results, we analyzed the association between different clinical outcomes and its association with IgG and IgM levels in a time dependent manner on the basis of time interval between symptom onset and IgM and IgG testing. As there is no gold standard diagnostic test for diagnosis of COVID-19, we used Bayesian latent class modelling for evaluation of the diagnostic performance of RT-PCR, IgM and IgG test in COVID-19.

Results:

Demographic characteristics:

A total of 494 hospitalized patients were enrolled in the retrospective study, among them 199 were RTPCR positive and 294 were clinically diagnosed COVID-19 patients (Table 1) (Figure 1 and 2).

Seropositivity status among COVID-19 patients

In this cohort of 494 patients, the seropositivity rate (i.e. either IgM or IgG >10 AU) was 247 (50%). Out of these IgM seropositivity was observed in 106/494 (47.97%) and for IgG 237/494 (21.45%). The Seropositivity rate was more for IgG compared to IgM. IgM or IgG seropositivity increased to a peak at week 4 then decreases after 4 weeks (> 28 days) (Figure 3) (Table 2 & 3).

Association between COVID-19 serology and RTPCR status:

There was a significant difference between the 2 groups in terms of IgM Levels (AU/mL) (W = 33428.000, p = <0.001) and IgG Levels (AU/mL) (W = 39256.500, p = <0.001) , with the median IgM/ IgG Levels (AU/mL) being highest in the RT-PCR-Positive group.

In all weeks There was a significant difference between the 2 groups in terms of IgM and IgG Levels (AU/mL) with the median IgM/ IgG Levels (AU/mL) being highest in the RT-PCR-Positive group. Except for week 4 (22-28 Days) there was no significant difference in terms of IgM and IgG Levels (AU/mL)

Association between COVID-19 serology and disease severity:

There was no significant difference between the groups in terms of IgM Levels (AU/mL) (χ 2 = 2.975, p = 0.395) and IgG levels (χ 2 = 2.463, p = 0.482).

In week 3, there was a significant difference between the 3 groups in terms of IgM Levels (AU/mL) ($\chi 2 = 7.732$, p = 0.021) and IgG Levels (AU/mL) ($\chi 2 = 7.707$, p = 0.021), with the median IgM and IgG Levels (AU/mL) being highest in the critical group. In all the other weeks There was a significant difference between the 2 groups in terms of IgM and IgG Levels (AU/mL)

Association of COVID-19 serology with ARDS types and Oxygen requirement:

There was a significant difference between the 4 groups in terms of IgM Levels (AU/mL) (χ 2 = 7.985, p = 0.046) and IgG Levels (AU/mL) (χ 2 = 8.501, p = 0.037). The median IgM Levels (AU/mL) being highest in the Mild ARDS group and median IgG Levels (AU/mL) being highest in the Moderate ARDS group.

In all weeks no significant difference between the groups in terms of IgM levels and IgG levels. However, in week 3 there was a significant difference between the 4 groups in terms of IgM Levels (AU/mL) (χ 2 = 10.837, p = 0.013) and IgG of IgG Levels (AU/mL) (χ 2 =

9.682, p = 0.021). The median IgM Levels (AU/mL) being highest in the Mild ARDS group and the median IgG Levels (AU/mL) being highest in the severe ARDS group.

There was a significant difference between the 3 groups in terms of IgM Levels (AU/mL) (χ 2 = 6.795, p = 0.033), with the median IgM Levels (AU/mL) being highest in the Oxygen Therapy: <6 L/min group. There was no significant difference between the groups in terms of IgG Levels (AU/mL) (χ 2 = 4.532, p = 0.104).

There was a significant difference between the 3 groups in terms of IgM Levels (AU/mL) in week 1 ($\chi 2 = 6.053$, p = 0.048), with the median IgM Levels (AU/mL) being highest in the Oxygen Therapy: <6 L/min group, week 2 ($\chi 2 = 6.392$, p = 0.041), with the median IgM Levels (AU/mL) being highest in the Oxygen Therapy: >6 L/min group and Week3 ($\chi 2 = 6.283$, p = 0.043), with the median IgM Levels (AU/mL) being highest in the Oxygen Therapy: <6 L/min group. There was a significant difference between the 3 groups in terms of IgG Levels (AU/mL) ($\chi 2 = 8.629$, p = 0.013), with the median IgG Levels (AU/mL) being highest in the Oxygen Therapy: >6 L/min group. In all other weeks no significant difference between the groups in terms of IgM levels and IgG levels

Association of COVID-19 serology with Septic shock:

There was no significant difference between the groups in terms of IgM Levels (AU/mL) (W = 1191.500, p = 0.168) and IgG Levels (AU/mL) (W = 19537.500, p = 0.261).

In all weeks no significant difference between the groups in terms of IgM levels and IgG levels. However, there was a significant difference between the 2 groups in terms of IgM Levels AU/mL) (W = 1827.000, p = 0.035), with the median IgM Levels (AU/mL) being highest in the no Septic Shock group. In week 3 IgG Levels (AU/mL) (W = 317.000, p = 0.022), with the median IgG Levels (AU/mL) being highest in the Septic Shock group and in > 4 week (W = 366.000, p = 0.042), with the median IgG Levels (AU/mL) being highest in the no Septic Shock group.

Association of COVID-19 serology with requirement of ICU admission:

There was no significant difference between the groups in terms of IgM Levels (AU/mL) (W = 23685.000, p = 0.668) and IgG (W = 25763.500, p = 0.157).

In all weeks no significant difference between the groups in terms of IgM levels and IgG levels. However, there was a significant difference between the 2 groups in terms of IgM

Levels (AU/mL) on week 3 (W = 403.500, p = 0.031) and IgG) (W = 460.000, p = 0.038) with the median IgM Levels (AU/mL) being highest in the group requiring ICU admission.

Association of COVID-19 serology with requirement of mechanical ventilation:

There was no significant difference between the groups in terms of IgM Levels (AU/mL) (W = 20744.500, p = 0.099) and IgG Levels (AU/mL) (W = 23067.000, p = 0.460).

In all weeks no significant difference between the groups in terms of IgM levels and IgG levels. However, there was a significant difference between the 2 groups in terms of IgM Levels (AU/mL) on week 2 (W = 2070.000, p = 0.035) and > 4 week (>28days) (W = 358.500, p = 0.033), with the median IgM Levels (AU/mL) being highest in the no Invasive Ventilation group.

Association of COVID-19 serology with acute kidney injury (AKI) and requirement of dialysis:

There was no significant difference between the groups in terms of IgM Levels (AU/mL) (W = 23261.500, p = 0.425) and IgG Levels (AU/mL) (W = 26023.500, p = 0.767).

In all weeks no significant difference between the groups in terms of IgM levels and IgG levels. However, there was a significant difference between the 2 groups in terms of IgM Levels (AU/mL) on week 2 (W = 2473.000, p = 0.008), and IgG Levels (AU/mL) (W = 2755.500, p = 0.043) with the median IgM/ IgG Levels (AU/mL) being highest in the no Acute Kidney Injury group.

There was a significant difference between the 2 groups in terms of IgM Levels (AU/mL) (W = 14962.000, p = <0.001), with the median IgM Levels (AU/mL) being highest in the no Dialysis group. However, there was no significant difference between the groups in terms of IgG Levels (AU/mL) (W = 14553.000, p = 0.206). In all weeks no significant difference between the groups in terms of IgM levels and IgG levels.

Association between COVID-19 serology and outcome: Survivor versus non-survivor

There was no significant difference between the groups in terms of IgM levels (AU/mL) (W = 21870.000, p = 0.058) and IgG levels (AU/mL) (W = 23088.500, p = 0.738).

In all the weeks there was no significant difference between the groups in terms of IgM levels and IgG levels. However, there was a significant difference between the 2 groups in terms of IgM Levels (AU/mL) on week 4 (W = 136.500, p = 0.032) and > 4 weeks (>

28days) (W = 575.500, p = 0.003) with the median IgM Levels (AU/mL) being highest in the survival group.

Discussion

The RT-PCR test is the most commonly used molecular test for the diagnosis of COVID-19 infection and is considered the gold standard test.(11) COVID-19 serology has emerged as one of the alternatives for diagnosing the COVID disease. One of the meta-analyses by Chen m et al showed that the panel of IgG+ or IgM+ had a sensitivity of almost 79%, followed by IgG+ IgM+/- (73%), IgG+/- IgM+ (68%). Pooled specificities of these tests ranged from 98% to 100%.(12) In this study also, in patients who had clinical COVID-19, almost 50% of patients were seropositive (IgM+ or IgG+).

COVID-19 IgG can be used as a tool to predict the disease severity. One of the retrospective studies done by yan x et al, showed that patients who had severe COVID-19 disease had higher COVID-19 IgG antibodies after 1 year.(13) In this study also patients who were RT-PCR positive had statistically significant COVID-19 antibody serology. Also, Seropositivity for IgG increases as disease severity increases as shown in this study.

In one of the cross-sectional studies done in Iran, the study suggested that the patients who were IgG and IgM positive had more severe symptoms compared to patients who had negative serology.(14) If we see the relationship between the COVID-19 serology and complications, not many studies had been done in the past .This study had shown that patients who had higher COVID-19 IgG levels at three weeks had more severe ARDS and oxygen requirements compared to other patients. We also observed that there was a statistically significant difference in IgG antibody titres between present or absence of septic shock at three weeks. A similar trend was seen for ICU admissions and the need for mechanical ventilation. Also, in patients, who developed AKI there was more IgG seropositivity than IgM.

Previous studies by Liu X. et al., 2020, Hou et al., 2020 and Zhang B. et al. (2020) showed that higher antibodies (IgM and IgG) levels are seen in patients with severe and critical patients compared to mild-moderate patients.(15-17) Chen, Hao, et al. 2021 study shows similar results as the above studies. However, the study showed antibody titres levels may vary and higher antibody titres were present in some patients' mild-moderate patients than in severe and critical patients. These findings are due to variation in serology to symptom onset interval.(18) The study also did not find a statistically significant correlation between

antibody tires with AKI, mechanical ventilation, ICU requirement, septic shock and

mortality.

This study shows that higher body titres are associated with poor outcomes at a particular

time serology to symptom onset interval. There are some limitations in this study first, its

retrospective study and dynamic observation variation in antibody tires with the outcomes

studied in a single patient. Second, there are limited patients in severe and critical patients

compared to mild and moderate which may lead to biases in the results.

Conclusion:

Serology (IgM and IgG) are inflammatory markers of COVID-19. In this study showed that

serology levels are high in RTPCR positive group compared to clinical COVID-19. However,

serology cannot be useful for the prediction of disease outcomes. The study also highlights

the importance of doing serology at a particular time as antibody titres vary with the duration

of the disease. In week interval there were significant correlation with clinical outcomes and

serology on week 3.

Contributors

All contributed to the data collection, data analysis, manuscript writing, critically reviewed

the draft, and approved it for publication.

Data sharing

It will be made available to others as required upon requesting the corresponding author.

Acknowledgment

COVID care team was collecting data, special thanks to all of them.

Conflicts of interest

We declare that we have no conflicts of interest.

Funding source

None

Reference

- **1.**COVID-19 Treatment Guidelines Panel.National Institutes of Health; 2022. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines;2022 Aug 8 (cited 2022 Aug 16). Available from: https://www.COVID19treatmentguidelines.nih.gov/.
- 2. COVID-19(Internet). CDC;2020.Assessing Risk Factors;2020 Nov 30(Cited 2022 Aug 16). Available from: https://www.cdc.gov/coronavirus/2019-ncov/COVID-data/investigations-discovery/assessing-risk-factors.html
- 3. Udwadia ZF, Tripathi AR, Nanda VJ, Joshi SR. Prognostic factors for adverse outcomes in COVID-19 infection. J Assoc Physicians India. 2020;68(7):56-60.
- 4. Sule WF, Oluwayelu DO. Real-time RT-PCR for COVID-19 diagnosis: challenges and prospects. The Pan African Medical Journal. 2020;35(Suppl 2).
- 5. Lekpa FK, Njonnou SRS, Balti E, Luma HN, Choukem SP. Negative antigen RDT and RT-PCR results do not rule out COVID-19 if clinical suspicion is strong. The Lancet Infectious Diseases. 2021.
- 6. Gupta-Wright A, Macleod CK, Barrett J, Filson SA, Corrah T, Parris V, et al. Falsenegative RT-PCR for COVID-19 and a diagnostic risk score: a retrospective cohort study among patients admitted to hospital. BMJ open. 2021;11(2):e047110.
- 7. Gong F, Wei H-x, Li Q, Liu L, Li B. Evaluation and comparison of serological methods for COVID-19 diagnosis. Frontiers in Molecular Biosciences. 2021;8.
- 8. Masiá M, Telenti G, Fernández M, García JA, Agulló V, Padilla S, et al., editors. SARS-CoV-2 seroconversion and viral clearance in patients hospitalized with COVID-19: Viral load predicts antibody response. Open forum infectious diseases; 2021: Oxford University Press US.
- 9. O Murchu E, Byrne P, Walsh KA, Carty PG, Connolly M, De Gascun C, et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review. Reviews in medical virology. 2021;31(2):e2162.
- 10. Phipps WS, SoRelle JA, Li Q-Z, Mahimainathan L, Araj E, Markantonis J, et al. SARS-CoV-2 antibody responses do not predict COVID-19 disease severity. American journal of clinical pathology. 2020;154(4):459-65.
- 11.WHO Coronavirus Disease (COVID-19) Technical Guidance:Laboratory Testing for 2019-nCoV in Humans.2020 https://www.who.int/emergencies/diseases/novelcoronavirus-2019/technical-guidance/laboratory-guidance
- 12. Chen M, Qin R, Jiang M, Yang Z, Wen W, Li J. Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review.

- Int J Infect Dis. 2021 Mar;104:415-422. doi: 10.1016/j.ijid.2021.01.016. Epub 2021 Jan 12. PMID: 33450372; PMCID: PMC7833601.
- 13. Yan X, Chen G, Jin Z, Zhang Z, Zhang B, He J, Yin S, Huang J, Fan M, Li Z, Chen F, Zeng Y, Han X, Zhu Y. Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19. J Med Virol. 2022 Jan;94(1):380-383. doi: 10.1002/jmv.27274. Epub 2021 Aug 21. PMID: 34403142; PMCID: PMC8426683.
- 14. Haghi Ashtiani MT, Sadeghi Rad P, Asnaashari K, Shahhosseini A, Berenji F, Mamishi S. Role of serology tests in COVID-19 non-hospitalized patients: A cross-sectional study. PLoS One. 2022 Apr 14;17(4):e0266923. doi: 10.1371/journal.pone.0266923. PMID: 35421183; PMCID: PMC9009643.
- 15. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506. doi: 10.1016/S0140-6736(20)30183-5
- 16. Liu, X., Zheng, X., Liu, B., Wu, M., Zhang, Z., Zhang, G., et al. (2020). Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, China. Aging 12, 12432–12440. doi: 10.18632/aging.103417
- 17. Zhang, B., Zhou, X., Zhu, C., Song, Y., Feng, F., Qiu, Y., et al. (2020). Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front. Mol. Biosci. 7:157. doi: 10.3389/fmolb.2020.00157
- 18.Chen H, Qin R, Huang Z, He L, Luo W, Zheng P, Huang H, Wang H, Sun B. Characteristics of COVID-19 patients based on the results of nucleic acid and specific antibodies and the clinical relevance of antibody levels. Frontiers in Molecular Biosciences. 2021 Jan 12;7:605862.

Figure 1:




Figure 2:




Figure 3:




Table 1: Basic characteristics of the cohort

Features	Mean ± SD Median (IQR) Min-Max Frequency (%)		
Age (Yrs)	48.95 ± 16.40 50.00 (36.00-61.00) 18.00 - 87.00		

Gender	
Male	326 (66.0%)
Female	168 (34.0%)
IgG(AU/mL)	29.66 ± 37.09 7.82 (0.63-57.07)
	0.00 - 176.60
IgG	
<10 AU/mL	257 (52.0%)
>10 AU/mL	237 (48.0%)
IgM (AU/mL)	30.14 ± 109.31 0.96 (0.48-7.68)
	0.16 - 949.66
IgM	
<10 AU/mL	358 (77.2%)
>10 AU/mL	106 (22.8%)
RT-PCR	
Positive	199 (40.4%)
Negative	294 (59.6%)
Onset-Testing	$19.87 \pm 30.53 \parallel 12.00 \ (7.00-21.00) \parallel$
Interval (Days)	1.00 - 302.00

Table 2: Comparison of the 2 Subgroups of the

Variable RT-PCR in Terms of IgM Levels (AU/mL):

Onset to testing interval	IgM Levels (AU/mL)	RT-PCR		Wilcoxon-Mann- Whitney U Test	
		Positive	Negative	\mathbf{W}	p value
Total sample (n=463)	Mean (SD)	45.65 (142.40)	19.83 (78.62)		<0.001
	Median (IQR)	2 (0.6-15.86)	0.7 (0.43-2.68)	33428.00	
	Range	0.24 - 949.66	0.16 - 873		
1-7 Days (n = 131)	Mean (SD)	55.52 (190.24)	14.80 (62.78)		0.016
	Median (IQR)	1.32 (0.56-6.81)	0.62 (0.4-2.45)	2333.000	
	Range	0.29 - 921.9	0.16 - 491.5		
8-14 Days (n = 126)	Mean (SD)	20.68 (34.17)	21.88 (71.89)		0.007
	Median (IQR)	5.27 (0.76-21.32)	0.7 (0.44-5.93)	2422.000	
	Range	0.24 - 147.9	0.22 - 484.7		
15-21 Days (n = 71)	Mean (SD)	97.30 (218.64)	29.32 (70.03)		0.044
	Median (IQR)	7.67 (0.9-59.94)	1.12 (0.56-19.05)	794.500	
	Range	0.32 - 949.66	0.24 - 333.4		
22-28 Days	Mean (SD)	34.46 (75.76)	16.26 (27.87)	172 000	0.244
	Median (IQR)	3.36 (1.06-15.96)	1.93 (0.42-17.29)	172.000	

Onset to testing	IgM Levels (AU/mL)	RT-PCR		Wilcoxon-Mann- Whitney U Test	
interval		Positive	Negative	W	p value
(n = 35)	Range	0.37 - 282.2	0.23 - 90.12		
>28 Days	Mean (SD)	41.33 (138.14)	6.07 (19.74)		
(n = 64)	Median (IQR)	1.35 (0.53-10.4)	0.54 (0.38-0.99)	692.500	0.011
	Range	0.25 - 700.8	0.2 - 105.2		

Onset to testing interval	IgG Levels RT-PCR		Wilcoxon-Mann- Whitney U Test		
	(AU/mL)	Positive	Negative	W	p value
Total sample (n = 493)	Mean (SD)	41.05 (39.03)	22.05 (33.72)	39256.50	<0.001
	Median (IQR)	34.7 (1.85-70.4)	2.1 (0.44-35.25)		
	Range	0.01 - 144.9	0 - 176.6		
1-7 Days	Mean (SD)	31.75 (37.54)	20.56 (34.17)		0.018
(n = 137)	Median (IQR)	11.43 (0.86-65.7)	1.92 (0.34-27.4)	2502.500	
	Range	0.26 - 111.7	0 - 176.6		
8-14 Days	Mean (SD)	47.28 (40.65)	23.43 (34.47)	3117.500	<0.001
(n = 137)	Median (IQR)	43.2 (6.06-77.1)	1.77 (0.56-39.59)		
	Range	0.01 - 144.9	0.02 - 106.8		
15-21 Days	Mean (SD)	44.87 (30.39)	30.65 (34.56)		
(n = 76)	Median (IQR)	52.09 (11.23-63.96)	11.69 (0.84-53.06)	932.000	0.016
	Range	0.48 - 93.44	0.21 - 122.89		
22-28 Days (n = 37)	Mean (SD)	54.37 (40.33)	38.22 (43.88)		
	Median (IQR)	45.67 (28.11-79.4)	7.81 (0.39-85.9)	194.000	0.236
	Range	0.36 - 143.63	0.27 - 103.1		
>28 Days (n = 67)	Mean (SD)	32.53 (37.34)	11.91 (22.91)		
	Median (IQR)	14.09 (1.58-58.1)	0.92 (0.4-10.76)	781.500	0.004
	Range	0.24 - 113.6	0.15 - 95.54		